Neoadjuvant therapy in HER2-positive breast cancer and interim PET

Lancet. 2025 Mar 29;405(10484):1054-1055. doi: 10.1016/S0140-6736(25)00256-9.

Authors

Elif Hindié¹, David Groheux²

Affiliations

¹ Nuclear Medicine Department, Bordeaux University Hospital, Bordeaux 33076, France. Electronic address: elif.hindie@chu-bordeaux.fr.
² Nuclear Medicine Department, Saint-Louis Hospital, Paris, France.

PMID: 40157798
DOI: 10.1016/S0140-6736(25)00256-9

No abstract available

Publication types

Letter